The most successful long-term outcomes often come from finding the right balance between effectiveness and tolerability, even if that means taking a slower approach to dose increases
BAC Between 0.08% to 0.15%: Significant impairment, including slurred speech and reduced motor skills
Evidence (sorafenib): A phase III, randomized, double-blind, placebo-controlled study (DECISION [NCT00984282]) evaluated the activity of sorafenib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[21] The trial included 417 patients with locally advanced or metastatic RAIrefractory thyroid cancer (papillary, follicular [including Hrthle cell], and poorly differentiated, not anaplastic tumors, defined as beyond well-differentiated tumors or those well-differentiated tumors that become resistant to radioiodine treatment) whose disease had progressed within the past 14 months
33 This article updates previous articles on this topic by Langan and Zawistoski, 4 and by Oh and Brown